TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30408155

Group type: EXPERIMENTAL
Intervention: Co-culturing normal MSCs with myeloma cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant IGFBP2
Number of subjects: 0

Group type: COMPARATOR
Intervention: MSCs from patients with MM
Number of subjects: 0

Group type: COMPARATOR
Intervention: IGFBP2+ small adipocytes
Number of subjects: 0
Study: 28196674

Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study: 26293573

Group type: EXPERIMENTAL
Intervention: Facilitated tucking position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Classical holding position
Number of subjects: 60
Study: 23749622

Group type: EXPERIMENTAL
Intervention: Standardized patient education program
Number of subjects: 434

Group type: COMPARATOR
Intervention: Traditional education program
Number of subjects: 434
Study: 21377691

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 19643809

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-fruit and -vegetable diet (strict adherence)
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1905
Study: 17466698

Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17P) 341 mg intramuscularly, twice each week until gestational week 36
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17P)
Number of subjects: 60
Study: 14731152

Group type: EXPERIMENTAL
Intervention: Primary care-based patient education programme
Number of subjects: 194
Study: 11583724

Group type: EXPERIMENTAL
Intervention: 17 beta E(2)‐D
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: CEE‐N
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (17 beta E(2)‐D and CEE‐N)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 8980206

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 439

Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 439
Study: 8102669

Group type: EXPERIMENTAL
Intervention: Vitamin A (50,000 IU)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 3521487

Group type: EXPERIMENTAL
Intervention: 8% arildone cream
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 29552942

Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate (LA) (n = 40)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 1.88 mg leuprorelin acetate (LA) (n = 40)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mirena implantation (n = 40)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mirena implantation after treatment with 3.75 mg LA (n = 40)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mirena implantation after treatment with 1.88 mg LA (n = 20)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: San-Jie-Zhen-Tong capsules alone (n = 20)
Number of subjects: 200
Study: 26986919

Group type: EXPERIMENTAL
Intervention: Parents and Tots Together (PTT) intervention, n = 27
Number of subjects: 48

Group type: COMPARATOR
Intervention: Attention-matched control home safety intervention, n = 21
Number of subjects: 48
Study: 25238251

Group type: EXPERIMENTAL
Intervention: GSK2374697 (AlbudAb)
Number of subjects: 0
Study: 22214264

Group type: EXPERIMENTAL
Intervention: Dementia-care mapping intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 19641984

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 23
Study: 17134892

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 3 years
Number of subjects: 1724

Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 3 years (in node-positive subgroup)
Number of subjects: 1724

Group type: COMPARATOR
Intervention: Control (in node-positive subgroup)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 3 years (in ER and PR positive subgroup)
Number of subjects: 1724

Group type: COMPARATOR
Intervention: Control (in ER and PR positive subgroup)
Number of subjects: 1724
Study: 15915033

Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia (4 days of continuous infusion of 4 ml/h bupivacaine, 0.125%, and 50 mug/ml morphine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 60
Study: 12495789

Group type: EXPERIMENTAL
Intervention: Ketamine psychotherapy (KPT) with a high dose of ketamine (2.0 mg/kg im)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ketamine psychotherapy (KPT) with a low dose of ketamine (0.2 mg/kg im)
Number of subjects: 70
Study: 7644901

Group type: EXPERIMENTAL
Intervention: Enriched commands (e.g., 'wave your hands as a conductor')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic commands (e.g., 'wave your hands')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elaboration
Number of subjects: 0
Study: 2671059

Group type: EXPERIMENTAL
Intervention: 0.25 mg of brotizolam
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 15 mg of flurazepam
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 939814

Group type: EXPERIMENTAL
Intervention: Self-instructional teaching of biostatistics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture method
Number of subjects: 0
Study: 31613133

Group type: EXPERIMENTAL
Intervention: Prioritizing positivity plus microintervention
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Initial exposure to either meditation type
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control passage
Number of subjects: 240
Study: 30771737

Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg bid)
Number of subjects: 6007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6007
Study: 28292385

Group type: EXPERIMENTAL
Intervention: Mitomycin-C injection 1 month before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mitomycin-C injection 24 hours before surgery
Number of subjects: 60
Study: 26086783

Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate‐containing securement dressing
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Non‐antimicrobial transparent dressings
Number of subjects: 1000
Study: 23782625

Group type: EXPERIMENTAL
Intervention: Orthodontic tooth movement initiated 2 to 4 weeks after tooth extraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Orthodontic tooth movement initiated >12 weeks after tooth extraction
Number of subjects: 40
Study: 20704642

Group type: EXPERIMENTAL
Intervention: 1% hydroalcoholic testosterone gel (50 mg/5 g gel), increased to 10 mg if clinically unsatisfactory
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 19558654

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP) 25/1.25 mg per kg on day 0
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Artesunate plus sulphadoxine-pyrimethamine (AS/SP) 25/1.25 mg per kg on day 0 plus 4 mg/kg artesunate on days 0, 1, and 2
Number of subjects: 411
Study: 17116835

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone plus azathioprine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral methylprednisolone plus mycophenolate mofetil
Number of subjects: 40
Study: 15490268

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily for 360 days
Number of subjects: 16
Study: 11309547

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg once daily, 400 mg on day 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9603272

Group type: EXPERIMENTAL
Intervention: Women's sensitive approach to drug-user treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment discharge status
Number of subjects: 0
Study: 7844298

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing resin in composite restoration
Number of subjects: 0
Study: 2451416

Group type: EXPERIMENTAL
Intervention: Whole grains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cracked grains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coarse flour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fine flour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fine maize meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole groats, rolled oats, fine oatmeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wheat flour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oat-based meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three cereals (wheat, maize, oats)
Number of subjects: 0
Study: 30402963

Group type: EXPERIMENTAL
Intervention: MMB-PLIF
Number of subjects: 101

Group type: COMPARATOR
Intervention: CO-PLIF
Number of subjects: 101
Study: 28272402

Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation (30g for 5 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 26515712

Group type: EXPERIMENTAL
Intervention: Modified Seeking Safety (25 sessions of 90 minutes each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Facilitated Twelve-Step (25 sessions of 90 minutes each)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Engaged in therapy (attended ≥ 6 sessions)
Number of subjects: 40
Study: 23053464

Group type: EXPERIMENTAL
Intervention: M4 (magnesium, 4 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 24
Study: 21741220

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 19170455

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Alcohol 101 Plus computer program
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: BMI and Alcohol 101 Plus computer program
Number of subjects: 198
Study: 17057135

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gelofusine
Number of subjects: 8
Study: 14688656

Group type: EXPERIMENTAL
Intervention: Optiva 2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Venflon 2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Biovalve
Number of subjects: 100
Study: 10686571

Group type: EXPERIMENTAL
Intervention: Continuous light handrail support
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Continuous very light handrail support
Number of subjects: 15

Group type: COMPARATOR
Intervention: No handrail support
Number of subjects: 15
Study: 9492915

Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate at a single dose rate of 10 mg/kg body weight
Number of subjects: 29

Group type: COMPARATOR
Intervention: Albendazole (single 400 mg dose)
Number of subjects: 29
Study: 7936563

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate (Timoptic)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.5% levobunolol (Betagan)
Number of subjects: 45
Study: 3555385

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 25 mg every two weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 5 mg every two weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate with dosage adjustment up to 10 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 25 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 5 mg
Number of subjects: 66
Study: 30062951

Group type: EXPERIMENTAL
Intervention: Magnum group (large femoral head)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional group (28 mm or 32 mm femoral head)
Number of subjects: 119
Study: 28043438

Group type: EXPERIMENTAL
Intervention: Baroreflex Activation Therapy (BAT) plus medical therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 140
Study: 25904747

Group type: EXPERIMENTAL
Intervention: Daily acyclovir treatment
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 23685637

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (0.5 μg/kg/min)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 41
Study: 20659400

Group type: EXPERIMENTAL
Intervention: Care plans (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no care plans)
Number of subjects: 0
Study: 18825772

Group type: EXPERIMENTAL
Intervention: CBir1 stimulation
Number of subjects: 0
Study: 16314619

Group type: EXPERIMENTAL
Intervention: Efaproxiral at 75 or 100 mg/kg
Number of subjects: 515

Group type: COMPARATOR
Intervention: Control (no efaproxiral)
Number of subjects: 515
Study: 14528576

Group type: EXPERIMENTAL
Intervention: Nursing with essential oils
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nursing without essential oils
Number of subjects: 40
Study: 10984077

Group type: EXPERIMENTAL
Intervention: Exercise (graded intensity: 1.5, 2.0, and 2.5 W/kg, 6 min each)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin (Actrapid MC Novo, 0.1 IU/kg, i.v.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral glucose (50 g and 100 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study: 9010703

Group type: EXPERIMENTAL
Intervention: Pranlukast (112.5 to 675 mg, oral, every 12 h)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Repeated dosing of pranlukast
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Evening doses of pranlukast
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 48
Study: 1476921

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) administered in fasting conditions
Number of subjects: 10

Group type: COMPARATOR
Intervention: 8-methoxypsoralen (8-MOP) administered after food ingestion (low-fat or fat-rich breakfast)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 8-methoxypsoralen (8-MOP) ingested with > 50% smaller quantity of food than usual
Number of subjects: 10
Study: 2870943

Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purified pork insulin
Number of subjects: 0
Study: 31620931

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and chemotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 40
Study: 30032191

Group type: EXPERIMENTAL
Intervention: ABT‐122 (RA, 120 mg; PsA, 240 mg) subcutaneously every other week on background MTX
Number of subjects: 326
Study: 27084589

Group type: EXPERIMENTAL
Intervention: Non-glucidic nutrients (50g of Parmesan cheese, one boiled egg)
Number of subjects: 8
Study: 24630262

Group type: EXPERIMENTAL
Intervention: RLAI 50mg biweekly
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: RLAI 100mg biweekly
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: RLAI 50mg and 100mg
Number of subjects: 160
Study: 24080920

Group type: EXPERIMENTAL
Intervention: larotaxel/cisplatin
Number of subjects: 337

Group type: COMPARATOR
Intervention: gemcitabine/cisplatin
Number of subjects: 337
Study: 19941058

Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive Transcranial Magnetic Stimulation (rTMS) applied to dorsolateral prefrontal cortex (DLFPC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 13
Study: 17765406

Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 301

Group type: COMPARATOR
Intervention: 70 Gy
Number of subjects: 301
Study: 16174272

Group type: EXPERIMENTAL
Intervention: Listerine mouthwash (10 ml, rinsed twice a day for 60 seconds)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.1% chlorhexidine (CHX) mouthwash (10 ml, rinsed twice a day for 60 seconds)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline solution (10 ml, rinsed twice a day for 60 seconds)
Number of subjects: 21
Study: 14604567

Group type: EXPERIMENTAL
Intervention: MVA-HIV-1(LAI)-nef vector vaccination
Number of subjects: 10
Study: 10390940

Group type: EXPERIMENTAL
Intervention: Psychodrama groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8667921

Group type: EXPERIMENTAL
Intervention: Longer maintenance chemotherapy (2 years)
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Vincristine and prednisone (VP) pulses during maintenance
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Intensive reinduction chemotherapy during maintenance
Number of subjects: 12000
Study: 1512053

Group type: EXPERIMENTAL
Intervention: Dynamic, continuous, computerized on-line vectorcardiography for real-time monitoring of QRS-complex and ST-segment changes.
Number of subjects: 15
Study: 6628528

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydroxylated metabolites (4' and 5 mono and dihydroxy derivatives)
Number of subjects: 16
Study: 30368495

Group type: EXPERIMENTAL
Intervention: Agility exergaming (EXE)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Stationary cycling (CYC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wait-listed control group (CON)
Number of subjects: 74
Study: 29265496

Group type: EXPERIMENTAL
Intervention: H. pylori eradication + proton pump inhibitor for 7 weeks
Number of subjects: 330

Group type: COMPARATOR
Intervention: Proton pump inhibitor for 8 weeks (non-eradication group)
Number of subjects: 330
Study: 26857107

Group type: EXPERIMENTAL
Intervention: Diet1 - advice to reduce saturated fat intake
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diet2 - Mediterranean Portfolio Diet with additional cholesterol-lowering foods (nuts, stanols, soya, oats, pulses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Score, 3-day food diaries and metabolomic biomarkers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Feasibility assessment
Number of subjects: 60
Study: 24337358

Group type: EXPERIMENTAL
Intervention: Biological condition (N=176)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control condition (N=175)
Number of subjects: 351
Study: 22596166

Group type: EXPERIMENTAL
Intervention: Multi-biomarker disease activity (MBDA) score
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Study therapy (intensive or conventional methotrexate-based treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MBDA score
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clinical variables
Number of subjects: 20
Study: 20634720

Group type: EXPERIMENTAL
Intervention: 0.3 mg moxonidine (MOX) daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 23
Study: 18225732

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 301
Study: 15897698

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 10 days
Number of subjects: 257

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily for 10 days
Number of subjects: 257
Study: 11916760

Group type: EXPERIMENTAL
Intervention: CSII plus 200 mg alpha-tocopherol/d
Number of subjects: 98

Group type: COMPARATOR
Intervention: CSII
Number of subjects: 98
Study: 9840721

Group type: EXPERIMENTAL
Intervention: Etoposide (100mg/m2/1 h) administered immediately before and at the end (24 h) of MTX treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoposide (100mg/m2/1 h) administered at 24 and 48 h after starting MTX infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose methotrexate (5g/m2/24 h)
Number of subjects: 0
Study: 7500751

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive (30 micrograms ethinyloestradiol)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Low-dose OCs with a third-generation progestagen
Number of subjects: 285
Study: 2225484

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg p.o. at -60 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: GHRH (100 micrograms, i.v. at 0 min)
Number of subjects: 6
Study: 495512

Group type: EXPERIMENTAL
Intervention: Single 5 mg oral dose of prazosin (Group A, no. = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral prazosin, 2 mg every 8 hours for 24 hours (Group B, no. = 7)
Number of subjects: 14
Study: 30909863

Group type: EXPERIMENTAL
Intervention: Karyotypic analysis of swamp buffaloes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Karyotypic analysis of crossbred buffaloes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Karyotypic analysis of murrah buffaloes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: D-loop mitochondrial DNA analysis
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Phylogenetic tree construction
Number of subjects: 105
Study: 28340281

Group type: EXPERIMENTAL
Intervention: FND followed by rituximab
Number of subjects: 158

Group type: COMPARATOR
Intervention: FND with concurrent rituximab
Number of subjects: 158
Study: 25636947

Group type: EXPERIMENTAL
Intervention: 12 DU of MK‐8237
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 6 DU of MK‐8237
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124